Cancer Chemotherapy and Pharmacology

, Volume 79, Issue 1, pp 49–55 | Cite as

Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma

  • Hui Zhang
  • Yan Guo
  • Yongsheng Song
  • Chao ShangEmail author
Original Article



Bladder cancer is the most general malignant cancer in genitourinary system, more than 90% of BCs are bladder transitional cell carcinomas (BTCC). This study aimed to investigate the clinical significance of growth arrest-specific 5 (GAS5) gene and its regulatory effects of malignant proliferation and chemotherapy resistance to doxorubicin in BTCC cells.


The expression of GAS5 was detected by quantitative real-time PCR. Statistical analysis was used to determine the relationship between GAS5 expression and clinical features and the prognostic value of GAS5 for disease free survival. MTT assay was used to detect cell proliferation ability and chemosensitivity. Dual-color flow cytometric method was used to detect cell apoptosis. The expression of Bcl-2 protein was examined by western blot.


In this study, we found that GAS5 low-expressed in BTCC tissues and cells, and its low expression level had positive correlation with higher pathological grades of BTCC. Moreover, GAS5 was a prognostic biomarker of disease free survival for BTCC patients. GAS5 over-expression could inhibit cell proliferation of BTCC J82 and T24 cells significantly. The IC50 to doxorubicin in T24/DOX cells (resistance to doxorubicin) presented a conspicuous depression, GAS5 enhancement reduced the chemotherapy resistance to doxorubicin. GAS5 over-expression promoted apoptosis induced by doxorubicin in T24/DOX cells, and depressed the expression of anti-apoptosis protein Bcl-2. The results indicated that GAS5 regulated the chemotherapy resistance to doxorubicin via Bcl2 partly.


In summary, lncRNA GAS5 was a prognostic biomarker of disease free survival in BTCC patients, and acted as a tumor-suppressing gene to inhibit malignant proliferation and resistance to doxorubicin in BTCC cells. LncRNA GAS5 might be a novel potential therapeutic target for BTCC.


Long noncoding RNA GAS5 Bladder transitional cell carcinoma Chemotherapy Doxorubicin 



This work was supported by the National Nature Science Foundation of China (81301834, 81172408, 30901480, 81272716).

Compliance with ethical standards

Conflict of interest



  1. 1.
    Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N (2007) Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 25:285–295CrossRefPubMedGoogle Scholar
  2. 2.
    Hassen W, Droller MJ (2000) Current concepts in assessment and treatment of bladder cancer. Curr Opin Urol 10:291–299CrossRefPubMedGoogle Scholar
  3. 3.
    Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P (2014) Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. Cancer Chemother Pharmacol 73(3):503–509CrossRefPubMedGoogle Scholar
  4. 4.
    Shang C, Guo Y, Zhang J, Huang B (2016) Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer. Cancer Chemother Pharmacol 77(5):1061–1067CrossRefPubMedGoogle Scholar
  5. 5.
    Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, Weng H, Shu YJ, Liu TY, Jiang L, Cao Y, Bao RF, Mu JS, Tan ZJ, Tao F, Liu YB (2014) MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther 15(6):806–814CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Carrieri C, Forrest AR, Santoro C, Persichetti F, Carninci P, Zucchelli S, Gustincich S (2015) Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells’ differentiation in vitro and in neurochemical models of Parkinson’s disease. Front Cell Neurosci 9:114CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Modali SD, Parekh VI, Kebebew E, Agarwal SK (2015) Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol 29(2):224–237CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, Zhou L, Zhou C, Yuan Q, Yang M (2015) Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration and invasion of esophageal squamous cell carcinoma cells. J Biol Chem 290(7):3925–3935CrossRefPubMedGoogle Scholar
  9. 9.
    Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, Yang X, Shen J, Liu Q, Zhang J (2016) Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumor Biol 37(2):2691–2702CrossRefGoogle Scholar
  10. 10.
    Gao J, Liu M, Zou Y, Mao M, Shen T, Zhang C, Song S, Sun M, Zhang S, Wang B, Zhu D, Li P (2015) Long non-coding RNA growth arrest-specific transcript 5 is involved in ovarian cancer cell apoptosis through the mitochondria-mediated apoptosis pathway. Oncol Rep 34(6):3212–3221PubMedGoogle Scholar
  11. 11.
    Guo X, Deng K, Wang H, Xia J, Shan T, Liang Z, Yao L, Jin S (2015) GAS5 inhibits gastric cancer cell proliferation partly by modulating CDK6. Oncol Res Treat 38(7–8):362–366CrossRefPubMedGoogle Scholar
  12. 12.
    Yu X, Li Z (2015) Long non-coding RNA growth arrest-specific transcript 5 in tumor biology. Oncol Lett 10(4):1953–1958PubMedPubMedCentralGoogle Scholar
  13. 13.
    Liu Z, Wang W, Jiang J, Bao E, Xu D, Zeng Y, Tao L, Qiu J (2013) Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS ONE 8(9):e73991CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Song J, Lee JE (2015) ASK1 modulates the expression of microRNA Let7A in microglia under high glucose in vitro condition. Front Cell Neurosci 9:198PubMedPubMedCentralGoogle Scholar
  15. 15.
    Yiwei T, Hua H, Hui G, Mao M, Xiang L (2015) HOTAIR Interacting with MAPK1 regulates ovarian cancer skov3 cell proliferation, migration, and invasion. Med Sci Monit 21:1856–1863CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shang C, Guo Y, Hong Y, Xue YX (2016) Long non-coding RNA TUSC7, a target of miR-23b, plays tumor-suppressing roles in human gliomas. Front Cell Neurosci 10:235CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang J, Yao T, Wang Y, Yu J, Liu Y, Lin Z (2016) Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21. Cancer Biol Ther 17(1):104–113CrossRefPubMedGoogle Scholar
  18. 18.
    Zhan Y, Liu Y, Wang C, Lin J, Chen M, Chen X, Zhuang C, Liu L, Xu W, Zhou Q, Sun X, Zhang Q, Zhao G, Huang W (2016) Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Oncotarget 7(13):16038–16048PubMedPubMedCentralGoogle Scholar
  19. 19.
    Zhu Y, Dai B, Zhang H, Shi G, Shen Y, Ye D (2016) Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis. Cancer Lett 380(2):369–374CrossRefPubMedGoogle Scholar
  20. 20.
    Chen T, Xie W, Xie L, Sun Y, Zhang Y, Shen Z, Sha N, Xu H, Wu Z, Hu H, Wu C (2015) Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer. Biochem Biophys Res Commun 468(4):666–670CrossRefPubMedGoogle Scholar
  21. 21.
    Zhao XL, Zhao ZH, Xu WC, Hou JQ, Du XY (2015) Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Int J Clin Exp Pathol 8(2):1954–1960PubMedPubMedCentralGoogle Scholar
  22. 22.
    Cao Q, Wang N, Qi J, Gu Z, Shen H (2016) Long non-coding RNA-GAS5 acts as a tumor suppressor in bladder transitional cell carcinoma via regulation of chemokine (C–C motif) ligand 1 expression. Mol Med Rep 13(1):27–34PubMedGoogle Scholar
  23. 23.
    Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W, Wei Q (2016) Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 7(19):27778–27786PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Hui Zhang
    • 1
  • Yan Guo
    • 2
  • Yongsheng Song
    • 1
  • Chao Shang
    • 3
    Email author
  1. 1.Department of Urinary Surgery, Shengjing HospitalChina Medical UniversityShenyangChina
  2. 2.Department of Central Laboratory, School of StomatologyChina Medical UniversityShenyangChina
  3. 3.Department of Neurobiology, College of Basic MedicineChina Medical UniversityShenyangChina

Personalised recommendations